High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1355-1361

  Hayashi, Kazuhiko ^a   Imaizumi, Toshihide ^a   Uchida, Kazumi ^a   Kuramochi, Hidekazu ^a   Takasaki, Ken ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

5 FU; Chemotherapy; Cisplatin; Pancreas

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CA 19-9 ANTIGEN; CISPLATIN; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; FEASIBILITY STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CISPLATIN; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PANCREATIC NEOPLASMS; PYRIDINES; SURVIVAL RATE; TEGAFUR;

EID: 0036835318     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1355     Document Type: Article

References (26)

1. Neiderhuber JE, Brennan MF and Menck HR: The national cancer data base report on pancreatic cancer. Cancer 76: 1671-1677, 1995.
2. Martin JL, Harvey HA, Lipton A and Martin R: Combined chemoradiotherapy for unresectable pancreatic cancer. Am J Clin Oncol 22: 309-314, 1999. (Pubitemid 30263330)
3. Lorenz M, Heinrich S, Staib-Sebler E, Kohne CH, Wils J, Nordlinger B and Encke A: Regional chemotherapy in the treatment of advanced pancreatic cancer is it relevant? Eur J Cancer 36: 957-965, 2000. (Pubitemid 30316419)
4. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V and Rosenbluth R: A phase III comparison trial of streptozotocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68: 965-968, 1991.
5. Moertel CG, Engstrom P and Lavin PT: Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combination of 5-fluorouracil with nitrosoureas and lactones. Surgery 85: 509-513, 1979. (Pubitemid 10207199)
6. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK and Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207-2212, 1990. (Pubitemid 20164823)
7. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 78: 654-663, 1996.
8. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
9. Shirasaka T, Nakano K, Fukushima M, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M-tegaful-0.4 M 5-chloro-2, 4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996. (Pubitemid 26171684)
10. Au JL and Sadee W: Activation of Ftorafur [R,S-1-(tetrahydro-2-furanyl)- 5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone. Cancer Res 40: 2814-2819, 1980.
11. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987. (Pubitemid 17132408)
12. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993. (Pubitemid 23267702)
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
14. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000. (Pubitemid 30411708)
15. Oettle H, Arnold D, Hempel C and Riess H: The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11: 771-786, 2000.
16. Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G and Scheithauer W: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 82: 98-103, 2000. (Pubitemid 30008966)
17. Kobayashi K, Shinbara A, Kamimura M, Takeda Y, Kabe J, Hibino S, Hino M, Shibuya M and Kudoh S: Irinotecan (CPT-11) in combination with weekly administration of cisplatin for non-small-cell lung cancer. Cancer Chemother Pharmacol 42: 53-58, 1998. (Pubitemid 28224991)
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, Oosteron AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
19. Rothenberg ML, Abbruzzese JL, Moore MJ, Portenoy RK, Robertson JM and Wanebo HJ: A rationale for expanding the endopoints for clinical trials in advanced pancreas carcinoma. Cancer 78: 627-632, 1996. (Pubitemid 26251522)
20. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J and Keim V: Decrease of CA19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82: 1013-1016, 2000. (Pubitemid 30128852)
21. Ahmed S, Vaitkevicius VK, Zalupski MM, Du W, Arlauskas P, Gordon C, Kellogg C and Shields AF: Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma. Am J Clin Oncol 23: 420-424, 2000. (Pubitemid 32429159)
22. Heinemann V, Schermuly MM, Stieber P, Schulz L, Jungust D, Wilkowski R and Schalhorn A: CA19-9: a predictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 19: 2433-2436, 1999.
23. Klapdor R, Seutter E, Lang-Polckow EM, Reichle H and Hinrichs A: Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 19: 2459-2470, 1999.
24. Safi F, Schlosser W, Falkenreck S and Begar HG: Prognostic value of CA19-9 serum course in pancreatic cancer. Hepatogastroenterology 45: 253-259, 1998. (Pubitemid 28067563)
25. Tian F, Appert HE, Myles J and Howerd JM: Prognostic value of serum CA19-9 levels in pancreatic adenocarcinoma. Ann Surg 215: 350-355, 1992.
26. Katz A, Hanlon A, Lanciano R, Hoffman J and Coia L: Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 41: 393-396, 1998. (Pubitemid 28243552)